Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons
Science Translational Medicine · 18.01.2023 · 15 (679)
DOI: 10.1126/scitranslmed.add4666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.01.2023. Verfasst von Junming Qian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cellular Biophysics, Columbia University Medical Center, Columbia University, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Rett Syndrome. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused by loss-of-function heterozygous mutations of methyl CpG-binding protein 2 ( MECP2 ) on the X chromosome in young females. Reactivation of the silent wild-type MECP2 allele from the inactive X chromosome (Xi) represents a promising therapeutic opportunity for female patients with RTT. Here, we applied a multiplex epigenome editing approach to reactivate MECP2 from Xi in RTT human embryonic stem cells (hESCs) and derived neurons. Demethylation of the MECP2 promoter by dCas9-Tet1 with target single-guide RNA reactivated MECP2 from Xi in RTT hESCs without detectable off-target effects at the transcriptional level. Neurons derived from methylation-edited RTT hESCs maintained MECP2 reactivation and reversed the smaller soma size and electrophysiological abnormalities, two hallmarks of RTT. In RTT neurons, insulation of the methylation-edited MECP2 locus by dCpf1-CTCF (a catalytically dead Cpf1 fused with CCCTC-binding factor) with target CRISPR RNA enhanced MECP2 reactivation and rescued RTT-related neuronal defects, providing a proof-of-concept study for epigenome editing to treat RTT and potentially other dominant X-linked diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Cellular Biophysics, Columbia University Medical Center, Columbia University, New York, NY 10032, USA.
- Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
- Department of Neurosurgery, Boston Children's Hospital, Boston, MA 02465, USA.
- Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
- Columbia Stem Cell Initiative, Columbia University Medical Center, Columbia University, New York, NY 10032, USA.
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Columbia University, New York, NY 10032, USA.
ORCID-Profile: Junming Qian, Xiaonan Guan, Bing Xie, Jacqueline Niu, Xin Tang, Charles H Li, Henry M Colecraft, Rudolf Jaenisch, X Shawn Liu
Förderung
- NICHD NIH HHS
- NIMH NIH HHS
Zitieren
APA
Qian, J., Guan, X., Xie, B., Xu, C., Niu, J., Tang, X., Li, C. H., Colecraft, H. M., Jaenisch, R., & Liu, X. S. (2023). Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. Science Translational Medicine, 15(679). https://doi.org/10.1126/scitranslmed.add4666
Vancouver
Qian J, Guan X, Xie B, Xu C, Niu J, Tang X, et al. Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. Science Translational Medicine. 2023;15(679). doi:10.1126/scitranslmed.add4666
BibTeX
@article{Qian2023,
author = {Qian, Junming and Guan, Xiaonan and Xie, Bing and Xu, Chuanyun and Niu, Jacqueline and Tang, Xin and Li, Charles H and Colecraft, Henry M and Jaenisch, Rudolf and Liu, X Shawn},
title = {Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {679},
doi = {10.1126/scitranslmed.add4666}
}
EUVIMED